Other GLP-1 RAs have ongoing CVOTs investigating CV safety in the GLP-1 RA class
Victoza® is the only GLP-1 RA recommended by the ADA to lower CVD event rates and mortality in patients with established CVD1
ADA/EASD=American Diabetes Association/European Association for the Study of Diabetes; CV=cardiovascular; CVD=cardiovascular disease; CVOT=cardiovascular outcomes trial; DPP-4=dipeptidyl peptidase-4; GI=gastrointestinal; GLP-1 RA=glucagon-like peptide-1 receptor agonist; OAD=oral antidiabetic drug; SGLT-2=sodium glucose cotransporter-2; SUs=sulfonylureas; TZDs=thiazolidinediones.
- American Diabetes Association. Standards of medical care in diabetes—2017. Diabetes Care. 2017;40(suppl 1):S1-S135.
- Trujillo JM, Wettergreen SA, Nuffer WA, Ellis SL, McDermott MT. Cardiovascular outcomes of new medications for type 2 diabetes. Diabetes Technol Ther.2016;18(12):1-10.
- Bydureon EXSCEL trial meets primary safety objective in type-2 diabetes patients at wide range of cardiovascular risk [new release]. AstraZeneca; May 23, 2017. https://www.astrazeneca-us.com/media/press-releases/2017/bydureon-exscel-trial-meets-primary-safety-objective-in-type-2-diabetes-patients-at-wide-range-of-cardiovascular-risk-05232017.html. Accessed May 24, 2017.
- Garber A, Abrahamson M, Barzilay J, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm–2016 executive summary. Endocr Pract. 2016;22(1):84-113.